A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France

PharmacoEconomics

Volumn 32, Issue 5, 2014, Pages 509-520

  Drummond, Michael ^a   De Pouvourville, Gerard ^b   Jones, Elizabeth ^c   Haig, Jennifer ^c   Saba, Grece ^b   Cawston, Hélène ^d  

^a UNIVERSITY OF YORK   (United Kingdom)

^b ESSEC BUSINESS SCHOOL   (France)

^c OPTUM   (United States)

^d OptumInsight   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; COMPARATIVE STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEASIBILITY STUDY; FRANCE; HEALTH CARE ACCESS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; UNITED KINGDOM; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; NEOPLASMS; PRESCRIPTION; STATISTICS AND NUMERICAL DATA;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG PRESCRIPTIONS; ENGLAND; FRANCE; HUMANS; NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; REIMBURSEMENT, INCENTIVE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84902328978     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0144-z     Document Type: Article

References (29)

1. Clement F, Harris MA, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. J Am Med Assoc. 2009;302:1437-43.
2. Lexchin J, Mintzes B. Medicine reimbursement recommendations in Canada, Australia, and Scotland. Am J Manag Care 2008;14:581-588, 194.
3. Bending M, Hutton J, McGrath C. A comparison of pharmaceutical reimbursement agencies' process and methods in France and Scotland. Int J Technol Assess Health Care. 2012;28(2):187.
4. Rawlins MD, Culyer AJ. National Institute of Clinical Excellence and its value judgments. Br Med J. 2004;329:224-7. (Pubitemid 39013284)
5. Shah KK, Cookson R, Culyer A, Littlejohns P. NICE's social value judgements (SVJ) about equity in health and health care. Health Econ Policy Law. 2013;8(2):145-65.
6. Sheldon T, Cullum AN, Dawson D, Lankshear A, Lowson K, Watt I, West P, Wright D, Wright J. What's the evidence that NICE guidance has been implemented? results from a national evaluation using time series analysis, audit of patients' notes and interviews. Br Med J. 2004;329:999.
7. Howard S, Harrison L. NICE guidance implementation tracking: data sources, methodology and results. Bicester: Abacus international; 2005.
8. National Institute for Health and Care Excellence. A guide to the methods of technology appraisal. London, July 2013. http://www.nice.org.uk/aboutnice/ howwework/devnicetech/guidetothemethodsoftechnologyappraisal.jsp.
9. National Institute for Health and Clinical Excellence. Business Plan 2011/2012 to 2014/15 Final. http://www.nice.org.uk/media/4B0/91/ FinalBusinessPlan20112015.pdf. Accessed 25 Apr 2013.
10. Cairns J. Providing guidance to the NHS: the Scottish Medicines Consortium and the National Institute for Clinical Excellence compared. Health Policy. 2006;76:134-43. (Pubitemid 43330597)
11. Barbieri M, Hawkins N, Sculpher M. Who does the numbers? the role of third-party technology assessment to Inform health systems' decision-making about the funding of health technologies. Value Health. 2009;12:193-201.
12. HAS. Bilan Social 2009. http://www.has-sante.fr/portail/upload/docs/ application/pdf/2010-11/bilan-social-2009.pdf.
13. Mason A, Drummond MF, Ramsey S, Campbell J, Raisch D. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J Clin Oncol. 2010;28(20):3234-8.
14. Barham L. Single technology appraisals by NICE: are they delivering faster guidance to the NHS? Pharmacoeconomics. 2008;26:1037-43.
15. HAS-Rapport d'activité de la Commission de la Transparence 2011. http://www.has-sante.fr/portail/upload/docs/application/pdf/ 2012-10/rapport-activite-commission-transparence-2011-vf.pdf. Accessed 24 Apr 2013.
16. Comité Economique des Produits de Santé. Rapport d'activité 2011. http://www.sante.gouv.fr/IMG/pdf/Rapport-Activite-CEPS- Final-2011-2.pdf. Accessed 24 Apr 2013.
17. House of Commons Health Committee. First report of session 2007-2008. London: The Stationary Office Limited; 2008.
18. House of Commons Health Committee. National Institute for Health and Clinical Excellence: NICE response to the Committee's first report of session 2007-2008. London: The Stationary Office Limited; 2008.
19. Drummond MF, Schwartz JS, Jönsson B, Luce BR, Neumann PJ. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008;24:244-58. (Pubitemid 351950160)
20. Ministère des Affaires Sociales et de la Santé. Internal control of the CEPS. http://www.sante.gouv.fr/the-internal-control-of-ceps.html.
21. http://www.legifrance.gouv.fr/. Accessed 16 Jan 2014.
22. Department of Health. A new value-based approach to the pricing of branded medicines: a consultation. London: Department of Health; 2010.
23. Inspectorate General for Social Affairs (IGAS). Rapport sur la pharmacovigilance et la gouvernance de la Chaîne du Médicaments. Report no RM2011-103P. http://www.igas.gouv.fr.
24. Mullard A. Mediator scandal rocks French medical community. Lancet. 2011;377(9769):890-2.
25. http://www.sante.gouv.fr/pilules-de-3eme-et-4eme-generation-contraceptif- oraux-combines.html23.
26. de Pouvourville G. HAS to be NICE? Eur J Health Econ. doi:10.1007/s10198-013-0463.
27. Prescrire. New drugs and new indications in 2010: inadequate assessment; patients at risk. http://english.prescrire.og/en/115/446/48385/2403/2399/ SubReportDetails.aspx.
28. HAS-Rapport d'activité de la Commission de la Transparence 2012. http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-10/ rapport-activite-commission-transparence-2012-vf.pdf. Accessed 20 Jan 2014.
29. Wilking N, Jonsson B. A pan-European comparison regarding access to cancer drugs. Stockholm, Karolinska Institutet and Stockholm School of Economics, 7 September, 2005.